Tag Archives: mesothelioma outcomes

Gender Differences in Men versus Women with Mesothelioma

Gender Differences in Men versus Women with Mesothelioma

Asbestos is toxic and cancer-causing for human beings. Asbestos causes mesothelioma and other asbestos related diseases. Asbestos-related diseases affect men and women differently. A recent study looked at Brazilian patients with asbestos-related diseases. These included mesothelioma, asbestosis, and lung and ovarian cancer. Introduction Mesothelioma, asbestosis, and pleural plaques are the main asbestos-related diseases. Many consider mesothelioma as the fingerprint of asbestos usage. Between 1961 and 2017, more 7 million tons of asbestos were consumed in Brazil. Mesothelioma from occupational exposure is most common in men. They were often exposed to asbestos at the job site. The number of non-occupational exposures is higher in women. Women are often exposed to asbestos from domestic and environmental sources. It has been difficult to … Continue reading Gender Differences in Men versus Women with Mesothelioma »

Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab

Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab

Canadian researchers say radiotherapy may hold the key to improving outcomes in mesothelioma. Mesothelioma is a fast-growing membrane cancer caused by asbestos. Doctors have not found a single therapy that can beat it. For most patients, a combination of treatments offer the best survival odds. Pembrolizumab plus Radiotherapy Pleural mesothelioma is a rare lung-related cancer caused by asbestos exposure. There is no cure for mesothelioma. Most mesothelioma patients have a combination of therapies. Radiation is one of the methods doctors use to help slow its spread. Outcomes in mesothelioma vary widely with the use of radiotherapy. Pembrolizumab is used in combination with chemotherapy as a first-line treatment for mesothelioma. Radiotherapy uses beams of intense energy to kill cancer cells. One … Continue reading Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab »